Journey MedicalDERM +1.83%62 Receivables Turnover is 0.58 as of Mar. 2026. GuruFocus rates DERM with a GF Score™ of 62/100 and a GF Value™ of $4.20 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 946 Drug Manufacturers companies, Journey Medical ranks worse than 81.29% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Journey Medical's Revenue for the
three
months ended in Mar. 2026 was $15.96 Mil. Journey Medical's average Accounts Receivable for the
three
months ended in Mar. 2026 was $27.39 Mil.
Hence, Journey Medical's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.58.
Journey Medical (NAS:DERM) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Journey Medical Receivables Turnover Related Terms
Journey Medical Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Journey Medical's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DERM vs LFCR, ANIK, ASRT: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Journey Medical's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Journey Medical Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Journey Medical's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Journey Medical's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Journey Medical (DERM) has a Receivables Turnover of 0.58 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Journey Medical and its competitors. According to the industry distribution chart, Journey Medical ranks #769 out of 946 companies in the Drug Manufacturers industry, placing it in the top 81.3%.
Is Journey Medical's Receivables Turnover too high?
Journey Medical's current Receivables Turnover is 0.58. The Drug Manufacturers industry median Receivables Turnover is 5.07. Journey Medical's value of 0.58 is 88.6% below this industry median. Based on the distribution chart, Journey Medical ranks #769 out of 946 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Journey Medical has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Journey Medical's Receivables Turnover compare to LFCR and ANIK?
According to the Drug Manufacturers industry distribution chart, Journey Medical ranks #769 out of 946 companies for Receivables Turnover. This places Journey Medical in the lower half of its industry. The industry median Receivables Turnover is 5.07. Journey Medical's value of 0.58 is 88.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Journey Medical's current Receivables Turnover of 0.58 is 88.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Journey Medical and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Journey Medical's current Receivables Turnover is 0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Journey Medical stock overvalued right now?
Based on GuruFocus' analysis, Journey Medical (DERM) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.20, compared to a current price of $7.22 — trading 71.9% above its estimated fair value. The current Receivables Turnover is 0.58 and 88.6% below the Drug Manufacturers industry median of 5.07. Journey Medical's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Journey Medical (DERM), the current Receivables Turnover is 0.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Journey Medical (DERM) Overvalued in 2026?
Based on GuruFocus' analysis, Journey Medical stock appears to be overvalued.
The current stock price of $7.22 is trading 71.9% above its estimated GF Value™ of $4.20.
GuruFocus considers Journey Medical to be Significantly Overvalued.
Key valuation signals for DERM:
Receivables Turnover: 0.58
GF Value™: $4.20 vs. price of $7.22 (71.9% above fair value)
Industry Position: 88.6% below the Drug Manufacturers median (#769 of 946)
No single metric tells the full story. See the DERM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
62GF Score
Get the complete analysis for DERM
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DERM has been successfully added to your 
